CMS Administrator Verma’s Statement on the Trump Administration’s Action to Expand Access to Quality, Affordable Health Coverage Through Health Reimbursement Arrangements
Coverage Leadership Legislation
Delay in Final Chimeric Antigen Receptor (CAR) T-cell therapy National Coverage Determination
From a CMS spokesperson:
Today, the Trump Administration finalized improvements to Medicare Advantage and Medicare Part D, which provide seniors with medical and prescription drug coverage through competing private insurance plans.
The Centers for Medicare & Medicaid Services (CMS) issued a final rule on May 16, 2019 that modernizes and improves the Medicare Advantage and Part D programs. These changes will ensure that patients have greater transparency into the cost of prescription drugs in Part D and will also enable Medicare Advantage plans to negotiate better prices for physician-administered medicines in Part C.
Agency issues guidance for Medicaid Managed Care and CHIP health plans that clarifies how current regulations require “spread pricing” to be accounted in the calculation of Medical Loss Ratios (MLRs)
Remarks by Administrator Seema Verma at the National Rural Health Association Annual Conference (As prepared for delivery – May 8, 2019)
Today at the Medical Device Manufacturers Association (MDMA) Annual Meeting, Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma for the first time walked through the agency’s comprehensive strategy to improve patients’ access to emerging technologies.